Key Drivers
- Strong liquidity
- Modest leverage
- Moderating cash flow
AIAI Summary
Penumbra's mid-teens revenue growth and promising thrombectomy pipeline are outweighed by the need to prove margin recovery and EPS conversion, as its premium valuation leaves little tolerance for further execution misses; investors should wait for clearer THUNDERBOLT commercialization and operating-leverage evidence before underwriting upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Modest leverage
- •Moderating cash flow
PEN has strong liquidity, low leverage, and solid profitability, but slowing cash conversion and an exceptionally high valuation leave little margin for execution setbacks.
Price Behavior
Key Price Behavior Insights:
- •Below average
- •Testing support
- •Weak momentum
PEN declined 1.9% over the last month and remains bearish below its $321.05 average, with $317.60 support critical and a recovery above $321.05 needed to improve momentum.
Gradual 1.9% decline over the last month
Sentiment & News
Key News Insights:
- •International expansion
- •Institutional buying
- •Margin pressure
Penumbra's expansion and institutional buying support growth prospects, but cost, margin, FX, and valuation concerns warrant cautious monitoring.
The mixed outlook may sustain investor interest while limiting near-term upside until profitability concerns ease
Similar Companies in Healthcare
Other companies in the same sector with AI ratings